Log In Get Started
Press Releases April 12, 2026 08:00 PM

Lamar Advertising Company to Release First Quarter Ended March 31, 2026 Operating Results

Lamar Advertising Company schedules Q1 2026 earnings release and conference call.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
LAMR

Lamar Advertising Company announced that it will release its first quarter ended March 31, 2026 operating results before the market opens on May 7, 2026. The company will host a conference call on the same day to discuss the results and company operations.

Lamar Advertising Company to Release First Quarter Ended March 31, 2026 Operating Results
LAMR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lamar Advertising plans to release Q1 2026 earnings on May 7, 2026, before market opening.
  • A conference call will be held at 8:00 a.m. Central Time to discuss results and answer questions.
  • Conference call access details and webcast replay information were provided.

BATON ROUGE, La., April 13, 2026 (GLOBE NEWSWIRE) -- Lamar Advertising Company (Nasdaq: LAMR) will release its first quarter ended March 31, 2026 earnings report before the market opens on Thursday, May 7, 2026. Lamar will host a conference call on Thursday, May 7, 2026 at 8:00 a.m. (Central time) to discuss the Company’s results and answer questions relating to company operations.

Instructions for dialing into Lamar’s conference call are provided below:

All Callers:1-800-420-1271 or 1-785-424-1634  Passcode:63104  Live Webcast:ir.lamar.com  Webcast Replay:ir.lamar.com   Available through Thursday, May 14, 2026 at 11:59 p.m. Eastern time


Company Contact:Buster Kantrow Director of Investor Relations (225) 926-1000 [email protected]

Risks

  • Potential earnings performance may differ from market expectations, impacting stock price volatility.
  • Advertising sector demand fluctuations could affect revenue and operational results.
  • Economic conditions influencing advertising budgets may pose uncertainties to company performance.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026